1. Neuropilin-1-Targeted Nanomedicine for Spatiotemporal Tumor Suppression through Photodynamic Vascular Damage and Antiangiogenesis.
- Author
-
Li XY, Yan N, Wu YY, Kong RJ, Qiu ZW, Liu SP, Wu DH, and Cheng H
- Subjects
- Humans, Animals, Mice, Female, Axitinib pharmacology, Axitinib chemistry, Axitinib therapeutic use, Nanomedicine, Apoptosis drug effects, Human Umbilical Vein Endothelial Cells, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Breast Neoplasms metabolism, Mice, Inbred BALB C, Cell Line, Tumor, Photosensitizing Agents pharmacology, Photosensitizing Agents chemistry, Photosensitizing Agents therapeutic use, Reactive Oxygen Species metabolism, Mice, Nude, Neuropilin-1 metabolism, Photochemotherapy, Angiogenesis Inhibitors pharmacology, Angiogenesis Inhibitors chemistry, Neovascularization, Pathologic drug therapy, Neovascularization, Pathologic pathology
- Abstract
Antiangiogenic therapy is an effective way to disrupt nutrient supply and starve tumors, but it is restricted by poor efficacy and negative feedback-induced tumor relapse. In this study, a neuropilin-1 (NRP-1)-targeted nanomedicine (designated as FPPT@Axi) is reported for spatiotemporal tumor suppression by combining photodynamic therapy (PDT) with antiangiogenesis. In brief, FPPT@Axi is prepared by utilizing an NRP-1-targeting chimeric peptide (Fmoc-K(PpIX)-PEG
8 -TKPRR) to encapsulate the antiangiogenic drug Axitinib (Axi). Importantly, the NRP-1-mediated targeting property enables FPPT@Axi to selectively concentrate at vascular endothelial and breast cancer cells, facilitating the production of reactive oxygen species (ROS) in situ for specific vascular disruption and enhanced cell apoptosis under light stimulation. Moreover, the codelivered Axi can further inhibit vascular endothelial growth factor receptor (VEGFR) to impair the negative feedback of PDT-induced tumor neovascularization. Consequently, FPPT@Axi spatiotemporally restrains the tumor growth through blocking angiogenesis, destroying tumor vessels, and inducing tumor apoptosis. Such an NRP-1-mediated targeting codelivery system sheds light on constructing an appealing candidate with translational potential by using clinically approved PDT and chemotherapy.- Published
- 2024
- Full Text
- View/download PDF